Sprycel 20mg Tablets| Dasatinib Side effects | MHP

1
SPRYCEL 20MG TABLETS DASATINIB SIDE EFFECTS
MHP

2
SYNOPSIS

• DESCRIPTION
• INDICATION
• MECHANISM OF ACTION
• PRODUCT DEATAILS
• PHARMACOKINETICS
• DOSAGE MANAGEMENT
• PRECAUTIONS
• SIDE EFFECTS
• DRUG INTERACTION
• MISSED DOSE
• LACTATION
• STORAGE
• CONTACT US

3
DESCRIPTION

• Sprycel 20mg is a second-generation receptor
  Tyrosine kinase inhibitor. Which binds to Abl
  with less stringent conformational needed so it
  exhibits increased effectiveness compared to
  Imatinib even though with less selectivity.
  Unlike most RTK inhibitors,
• Sprycel 20mg linked the active conformation of
  Bcr-Abl. Is required to treat patients with some
  Imatinib resistant forms of CML
• Sprycel 20mg which used as prescription drug
  under the guidance of doctor.

4
INDICATION

• Sprycel 20mg is used for the treatment for
  Chronic Myeloid Leukaemia Recently diagnosed
  adults with Philadelphia chromosome-positive
  (Ph) chronic myeloid leukaemia (CML) in chronic
  phase.Severe, increased, or myeloid or lymphoid
  blast phase Ph CML with resistance or
  intolerance to prior therapy including
  imatinib.Sprycel 20mg is used for the treatment
  for Acute Lymphoblastic Leukaemia Philadelphia
  chromosome-positive (Ph) acute lymphoblastic
  leukaemia (ALL) with resistance or intolerance to
  prior therapy

5
MECHANISM OF ACTION

• Sprycel 20mg is used for the treatment for
  Chronic Myeloid Leukaemia Recently diagnosed
  adults with Philadelphia chromosome-positive
  (Ph) chronic myeloid leukaemia (CML) in chronic
  phase.
• Severe, increased, or myeloid or lymphoid blast
  phase Ph CML with resistance or intolerance to
  prior therapy including imatinib.
• Sprycel 20mg is used for the treatment for Acute
  Lymphoblastic Leukaemia Philadelphia
  chromosome-positive (Ph) acute lymphoblastic
  leukaemia (ALL) with resistance or intolerance to
  prior therapy

6
PRODUCT DEATAILS

• Brand Sprycel Ingredients Dasatinib Strength
  20mg Manufactured BMS India Pvt ltd Package
  60 tablets

7
SPRYCEL 20MG
8
PHARMACOKINETICS

• Plasma protein binding is 96volume of
  distribution 2505 L Extensively metabolized in
  humans, mainly by the cytochrome P450 enzyme
  3A4.Dasatinib excreted through the
  feces. Half-life is 3-5 hours

9
DOSAGE MANAGEMENT

• Newly diagnosed The prescribed dose for
  Chronic Myeloid Leukaemia is starting 100 mg PO
  qDay (morning or evening). The drug will be
  raised to 140 mg qDay if insufficient response.
  The prescribed dose for Advanced CML is starting
  140 mg PO qDay. The drug will increase to 180 mg
  qDay if insufficient reactions The prescribed
  dose for Acute Lymphoblastic Leukaemia is
  starting 140 mg PO qDay. The drug will increase
  to 180 mg PO qDay if insufficient reactions

10
PRECAUTIONS

• When combination with chemotherapy the paediatric
  patients with Ph ALL treated, execute CBCs prior
  to initial of each block of chemotherapy and as
  clinically indicated during consolidation blocks
  of chemotherapy, do CBCs every 2 days until
  recovery
• During treatment with Sprycel will causes
  Myelosuppression includes serious
  thrombocytopenia, neutropenia and Anemia may
  develop may manage by dose interruption, dose
  reduction, or stopping of treatment
  hematopoietic growth factor has been used with
  resistant myelosuppression.

11
SIDE EFFECTS

• Dyspnea  Anorexia  Arthralgia  Asthenia 
  Constipation  Dizziness  Musculoskeletal
  pain  Febrile neutropenia Thrombocytopenia
  Mucosal inflammation  Anemia  Skin rash 
  Infection  Nausea  Diarrhea  Headache 
  Haemorrhage Fatigue  Pyrexia

12
DRUG INTERACTION

• Sprycel 20mg concomitant use with CYP3A4
  inhibitors will have high Dasatinib plasma
  concentration.
• Sprycel 20mg concomitant use with CYP3A4 inducers
  will lowers Dasatinib plasma concentration.
• Sprycel 20mg concomitant use with antacids will
  lower Dasatinib plasma concentration.
• Sprycel 20mg concomitant use with H2
  antagonists/proton pump inhibitors will lowers
  Dasatinib plasma concentration.
• Sprycel 20mg concomitant use with CYP3A4
  substrates will have their plasma concentration
  changed by Dasatinib.

13
MISSED DOSE

• If missed dose occurs, patients must consult with
  medical oncologist and follow the regular dosing
  schedule.

14
PREGNANCY

• Pregnancy category D Sprycel 20mg will resulted
  in fetal harm during pregnancy. Discuss with
  pregnant woman of the possible risk to a foetus.

15
LACTATION

• Avoid breast feeding during Sprycel treatment

16
STORAGE

• Stored at 20C 25C

17
CONTACT US

• MOBILE NO 91-9940472902EMAIL millionhealthphar
  maceuticals_at_gmail.com
• WEBSITE URLhttps//millionpharma.com/sprycel-20mg
  .php